Breaking News, Collaborations & Alliances

Ailux, Lilly Partner to Advance Bispecific Antibody Development

Through this collaboration, Lilly will gain access to Ailux's AI-powered bispecific antibody engineering platform.

Author Image

By: Charlie Sternberg

Associate Editor

Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi, has announced a strategic platform-based collaboration with Eli Lilly and Company to accelerate the discovery and development of bispecific antibodies for the treatment of various diseases. Through this collaboration, Lilly will gain access to Ailux’s AI-powered bispecific antibody engineering platform, which integrates advanced structural modeling, generative design, and developability analytics to del...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters